Figure 5: Multiple components of a Hippo pathway are regulated by miR-135b.

(a) CL1-0 cells were co-transfected with control vector (Ctrl vector) or miR-135b-expressing plasmids with firefly luciferase fused with 3′-UTR sequences of putative miR-135b target genes. Luciferase activity was measured, and the relative ratio of activity in the miR-135b groups to that in the control vector groups is presented as the mean±s.d., *P<0.05; **P<0.01 by Student’s t-test. (b) CL1-0 cells co-transfected with miR-135b and pGL3-3′-UTRs with scramble (NC) or Antago-135b for 60 h. Luciferase activity was assayed and is presented as described in (a). Mean±s.d. is shown, *P<0.05; **P<0.005 by Student’s t-test. (c) Western blot analysis of the Hippo pathway components in CL1-0 and HEK-293 cells transduced with control (Neo) or miR-135b lentiviral vectors. (d) Western blot analysis of Hippo pathway proteins in CL1-5-F4 and CL-141 cells incubated with Scramble (NC) or Antago-135b for 72 h. Quantitative RT–PCR was used to assay miR-135b knockdown activity. (e) Endogenous TAZ proteins in CL1-0 cells transfected with control (pCIneo), miR-135b, miR-135+ LATS2. The cells were harvested after 36 h of transfection.